Investment Rating - The investment rating for the company is "Buy" (maintained) [1][15] Core Insights - The company achieved total revenue of 13.042 billion HKD in 2025, representing a year-on-year growth of 38.4%. Product sales revenue reached 11.896 billion HKD, up 44.6% year-on-year. The company reported a net profit of 814 million HKD under IFRS, compared to a loss of 95 million HKD in 2024, and a Non-IFRS net profit of 1.723 billion HKD. This growth is attributed to the leading position in oncology products and rapid expansion in cardiovascular and metabolic product lines. The company has also entered a global strategic collaboration with Takeda Pharmaceutical, which will gradually confirm high upfront payments in the coming years. The profit forecasts for 2026-2027 have been raised, with expected net profits of 2.178 billion HKD, 2.504 billion HKD, and 2.960 billion HKD for 2026, 2027, and 2028 respectively, leading to a current price-to-earnings ratio of 77.0, 67.0, and 56.6 times [6][10]. Financial Summary - The company’s total revenue is projected to reach 18.515 billion HKD in 2026, with a year-on-year growth of 42.0%. The net profit is expected to increase to 2.178 billion HKD, reflecting a growth of 167.7% compared to 2025. The gross margin is anticipated to be 86.8%, and the net margin is expected to be 11.8% [10][12]. Global Expansion and Innovation - The company is accelerating its global layout, with multiple innovative pipelines entering global MRCT. The core product IBI363 has initiated a global MRCT Phase III clinical study for IO-resistant squamous NSCLC. IBI343 has received two BTD designations from NMPA and FTD from the FDA, with its first international Phase III study for third-line gastric cancer ongoing in China and Japan. IBI324 is expected to start an international Phase III clinical study in 2026 [7][8]. Future Product Pipeline - The next-generation pipeline focuses on oncology with IO+ADC technologies, including IBI363, IBI343, IBI3003, bispecific ADCs, and dual payload ADCs. These aim to enhance treatment standards or address unmet needs in various fields. Several pipelines are currently in international Phase I clinical studies [8]